Table 1.

Patient demographics, reasons for colonoscopy, and comorbidities.

Parameter	AJG522*	PEG + E†	Total
Number (%) of cases	32	33
Age (yr)			0.369
Median	60	67
Range	26–82	25–84
Gender, N (%)			0.622
Male	16 (50.0%)	16 (48.5%)
Reason for colonoscopy, N (%)			0.055
Abdominal pain	2 (6.3%)	4 (12.1%)
Bloody stool	5 (15.6%)	6 (18.2%)
Follow-up after polypectomy	5 (15.6%)	8 (24.2%)
Diarrhea	0 (0%)	3 (9.1%)
Constipation	1 (3.1%)	2 (6.1%)
Tumor screening	3 (9.4%)	4 (12.1%)
Anemia	2 (6.3%)	0 (0%)
Inflammatory bowel disease	12 (37.5%)	4 (12.1%)
Other	2 (6.3%)	2 (6.1%)
Comorbidities, N (%)			0.518
Diabetes mellitus	5 (15.6%)	2 (6.1%)
Hypertension	12 (37.5%)	5 (15.2%)
Rheumatoid arthritis	2 (6.3%)	0 (0%)
Chronic kidney disease	1 (3.1%)	0 (0%)

^*AJG522: the solution contained 100.0 g macrogol 4000, 7.5 g sodium sulfate, 2.7 g sodium chloride, 1.0 g potassium chloride, 4.7 g ascorbic acid, 5.9 g sodium ascorbate, and green apple flavoring per liter; total dose = 2 L. ^†PEG + E (Niflec): the solution contained 59.0 g macrogol 4000, 5.7 g sodium sulfate, 1.5 g sodium chloride, 0.7 g potassium chloride, 1.7 g sodium bicarbonate, and lemon flavoring per liter; total dose = 2 L.